Commentary on “Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomized, placebo-controlled trial.” M.R. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi, B. Tombal, K. Miller, P. Sieber, L. Karsh, R. Damião, T.L. Tammela, B. Egerdie, H. Van Poppel, J. Chin, J. Morote, F. Gómez-Veiga, T. Borkowski, Z. Ye, A. Kupic, R. Dansey, C. Goessl, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.: Lancet 2012;379:39–46 [Epub;2011, November 15]

Autor: Trump, Donald L.
Zdroj: In Urologic Oncology: Seminars and Original Investigations September-October 2012 30(5):747-747
Databáze: ScienceDirect
Externí odkaz: